January 6, 2022: Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
Read More…

April 20, 2021: Dirk Sauer, Ph.D. Joins Iconic Therapeutics’ Board of Directors
Read More…

December 2, 2020: Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application.
Read More…

September 15, 2020: Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-In-Class Potential For ICON-2 In Treatment Of Solid Tumors
Read More…

August 22, 2019: Iconic Therapeutics Signs Ophthalmology Option Agreement
Read More…

May 16, 2019: Iconic Therapeutics and Exelixis enter into an exclusive option and license agreement for ICON-2
Read More…

May 14, 2019: Iconic Therapeutics Enters Licensing Agreement with Zymeworks for ZymeLink^TM Antibody-Drug Conjugate Platform
Read More…

May 16, 2018: Iconic Therapeutics Initiates Second Phase 2 Study of ICON-1 in Patients with
Neovascular (wet) AMD; DECO Study to Explore Dosing Regimen with Higher ICON-1 Dose
Read More…

August 22, 2017: Iconic Therapeutics Appoints Brandon Smith Chief Operating Officer
Read More…

April 6, 2017: Iconic Therapeutics Appoints Julia P. Gregory To Board Of Directors
Read More…

February 9, 2017: Iconic Therapeutics To Present Phase 2a EMERGE Trial Results at Miami Meeting
Read More…

August 9, 2016: Iconic Therapeutics Announces Final Close Of Series C Financing With Additional $10 Million Investment.
Read More…

January 11, 2016: Iconic Therapeutics Closes Series C Financing with New and Existing Investors
Read More…

May 12, 2015: K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific Advisor
Read More…

April 16, 2014: Iconic Therapeutics Raises $20 Million to Advance Clinical Development of Wet AMD Program
Read More…